Founded in 2010, NephroPlus is a uniquely positioned dialysis provider operating in sizeable, high-growth markets across Asia with dominant leadership in India and a fast-growing footprint in the Philippines and other Asian countries.
NEW DELHI – May 6, 2024. Quadria Capital (“Quadria”), one of Asia’s largest healthcare-focused private equity firms, today announced an investment of INR 850 Crores in NephroPlus, Asia’s largest dialysis network. Through this transaction, Quadria will acquire a significant minority stake through a combination of a primary investment and the purchase of shares from existing shareholders. The transaction will support NephroPlus in serving the growing demand for high quality, affordable dialysis services across India and other markets in Asia.
Founded in 2010, NephroPlus is a uniquely positioned dialysis provider operating in sizeable, high-growth markets across Asia with dominant leadership in India and a fast-growing footprint in the Philippines and other Asian countries. The company serves patients across dialysis centres in marquee hospitals and at standalone clinics, working with leading nephrologists. NephroPlus also delivers care through public-private partnerships in both urban and rural areas.
Demand for dialysis services in the company’s target markets is expected to grow at a rate of over 11% annually over the next five years. Specialized chains such as NephroPlus are expected to gain market share as hospitals increasingly outsource dialysis operations and as governments seek to make high-quality dialysis services more accessible. The company has a successful track record of growing via bolt-on acquisitions and plans to do more acquisitions in the future. With Quadria’s support, NephroPlus aims to leverage its strong brand, operational expertise, and trusted relationships with leading nephrologists to capitalise on growth opportunities and expand its market leadership.
Vikram Vuppala, Founder and CEO of NephroPlus, said: “Our business has evolved tremendously over the past few years and today we are proud to be one of the fastest growing and most trusted providers of high-quality dialysis to around 30,000 patients. We look forward to expanding in India, our core market, while exploring further opportunities to bring our expertise and clinical excellence to more patients in other global markets. Quadria’s healthcare expertise, capital and focus on operational value creation will put us in an even better position to keep scaling, innovating, and delivering affordable and high-quality care.”
Sunil Thakur, Partner and Head of South Asia at Quadria Capital, said: “Quadria’s investment in NephroPlus underscores our ambition to invest in regional champions of Asian healthcare, who are providing high-quality, affordable healthcare to large, under-served populations. NephroPlus has demonstrated its ability to significantly improve health outcomes for its patients, whilst maintaining industry-leading growth and profitability. We look forward to working with their leadership team to continue to expand their footprint, increase access to dialysis services across Asia and accelerate the next phase of growth for NephroPlus.”
Quadria has a strong track-record of successful investments in some of India’s leading single-specialty healthcare companies including Maxivision, one of India’s leading eye care chains; AIG, a leading global referral centre for gastroenterology; and HCG, India’s leading oncology network.
About NephroPlus
NephroPlus operates around 450 dialysis centers in 250+ towns and cities across India, the Philippines and Uzbekistan, offering quality, affordable services to around 30,000 of patients and performing over 3 million dialysis sessions each year. Founded in 2010 with a vision to enable patients on dialysis to lead long, happy and productive lives, NephroPlus has established itself as one of Asia’s largest and fastest growing dialysis networks. Focused on clinical excellence, constant process improvement and innovation, the company was awarded the Innovation Award at the 14th Aegis Graham Bell Awards for its patented dialyzer reprocessing machine in February 2024.
For more information, please visit www.nephroplus.com
About Quadria Capital
Founded in 2012, Quadria is an Asia healthcare-focused private equity firm with assets under management of over US$3.4 billion, maximising returns by investing in the high growth healthcare sector of some of the world’s fastest-growing economies in South Asia and Southeast Asia, including Healthcare Delivery, Life Sciences, Medical Technology and Associated Healthcare Services subsectors. The firm aims to create significant and sustainable shareholder value by supporting strong, professionally run, stable and scalable healthcare organisations to address the critical and undersupplied healthcare needs in Asia.
For more information, please visit www.quadriacapital.com
Investor Relations Contact
Gerald Ng, Head of Investor Relations
Email: [email protected]